GNT Biotech & Medicals Co. Ltd., of Taipei, Taiwan, said it awarded exclusive sales and marketing rights in Taiwan of cancer drug chidamide to pharmaceutical distribution company Taiwan Specialty Pharma Corp. for two indications: hormone receptor-positive, HER2-negative, late-stage breast cancer in postmenopausal patients and peripheral T-cell lymphoma. The licensing agreement includes up-front and milestone payments of up to NT$30 million (US$1 million), with royalties from sales to be awarded separately.